// App-Quantinova.ai

4143 : Association Between Busulfan First-Dose Pharmacokinetics and Outcome in Children Receiving Myeloablative Busulfan-Based Conditioning Before Unrelated Umbilical Cord Blood Transplantation for Malignancies

Researchers

Presenter

  • Mohamed Aziz Rezgui

Principal Investigators

  • Samira Meziani

  • Marie-France Vachon

  • Catherine Desjean

  • Michel Duval

  • Yves Theoret

  • Maja Krajinovic

  • Marc Ansari

Medical Centers

  • Department of Paediatrics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada

  • Centre de Cancerologie Charles-Bruneau, CHU Sainte-Justine, Montreal, Canada

  • Department of Pediatrics, Onco-Haematology unit, Geneva University Hospital, Faculty of Medicine, Geneva, Switzerland

  • CHU Sainte-Justine Research Center, Charles-Bruneau Cancer Center, Montreal, Canada

  • Department of Paediatrics, Division of Hematology-Oncology, Sainte-Justine Hospital, Montreal, Canada, QC, Canada

Locations

  • Canada

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Graft-versus-host disease

  • Acute Leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Cluster of Differentiation 34

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • cyclosporin A

  • cyclosporin

  • Etoposide

  • Etoposide phosphate

  • Melphalan

  • Busulfan

Outcome

  • N/A

Study Design

  • pharmacokinetics

  • fixed dose

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved